Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Status:
Recruiting
Trial end date:
2022-11-17
Target enrollment:
Participant gender:
Summary
This phase I/IIa trial studies the best dose and side effects of rintatolimod and interferon
(IFN) alpha-2b in treating cancer patients with COVID-19 infection. Interferon alpha is a
protein important for defense against viruses. It activates immune responses that help to
clear viral infection. Rintatolimod is double stranded ribonucleic acid (RNA) designed to
mimic viral infection by stimulating immune pathways that are normally activated during viral
infection. Giving rintatolimod and interferon alpha-2b may activate the immune system to
limit the replication and spread of the virus.